<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00180128</url>
  </required_header>
  <id_info>
    <org_study_id>MK1-192</org_study_id>
    <nct_id>NCT00180128</nct_id>
  </id_info>
  <brief_title>AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia</brief_title>
  <official_title>AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia(APL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <brief_summary>
    <textblock>
      In AIDA 2000 therapy of acute promyelocytic leukemia (APL) is given in a risk-adapted manner.
      Risk factors are age and white-blood-cell (WBC)-count at diagnosis. Induction therapy is done
      with ATRA and idarubicin followed by postremission therapy with daunorubicin and mitoxantrone
      in age adapted dosages. Patients with an high WBC were additionally treated with cytarabine.
      Finally a two year period of maintenance therapy with 6-mercaptopurine, methotrexate and ATRA
      is performed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In AIDA 2000 therapy of acute promyelocytic leukemia (APL) is given in a risk-adapted manner.
      Risk factors are age and white-blood-cell (WBC)-count at diagnosis. Induction therapy is done
      with ATRA and idarubicin followed by postremission therapy with daunorubicin and mitoxantrone
      in age adapted dosages. Patients with an high WBC were additionally treated with cytarabine.
      Finally a two year period of maintenance therapy with 6-mercaptopurine, methotrexate and ATRA
      is performed.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2000</start_date>
  <completion_date type="Anticipated">November 2012</completion_date>
  <primary_completion_date type="Anticipated">November 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>toxicity of the regimen</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluation of additional risk factors</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effectiveness of MRD as guidance for therapy decisions</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete remission rate</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Leukemia, Promyelocytic, Acute</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>all-trans retinoid acid</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>idarubicin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daunorubicin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  acute promyelocytic leukemia confirmed by detection of t(15;17) and/or PML/RARa

          -  no contraindication for chemotherapy

          -  written informed consent

        Exclusion Criteria:

        - severe comorbidities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerhard Ehninger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine I, University Hospital Carl Gustav Carus Dresden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Markus Schaich, MD</last_name>
    <phone>+49-351-458</phone>
    <phone_ext>-4251</phone_ext>
    <email>markus.schaich@uniklinikum-dresden.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Silke Soucek</last_name>
    <phone>+49-351-458</phone>
    <phone_ext>-4251</phone_ext>
    <email>silke.soucek@uniklinikum-dresden.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Medicine I, University Hospital Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Schaich, MD</last_name>
      <phone>+49-351-458</phone>
      <phone_ext>-4251</phone_ext>
      <email>markus.schaich@uniklinikum-dresden.de</email>
    </contact>
    <contact_backup>
      <last_name>Silke Soucek</last_name>
      <phone>+49-351-458</phone>
      <phone_ext>-4251</phone_ext>
      <email>silke.soucek@uniklinikum-dresden.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>July 8, 2011</last_update_submitted>
  <last_update_submitted_qc>July 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Gerhard Ehninger</name_title>
    <organization>Dresden University of Technology</organization>
  </responsible_party>
  <keyword>acute promyelocytic leukemia</keyword>
  <keyword>risk adapted therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

